Kubbutat MH[au] - Search Results

Year	Number of Results
1994	2
1995	2
1997	2
1998	4
1999	3
2000	2
2001	1
2003	1
2005	1
2006	1
2007	2
2008	3
2009	7
2010	4
2011	5
2012	4
2013	2
2014	1
2016	1
2017	2
2018	2
2019	1
2021	1
2022	0

1

7-(2-Anilinopyrimidin-4-yl)-1-benzazepin-2-ones Designed by a "Cut and Glue" Strategy Are Dual Aurora A/VEGF-R Kinase Inhibitors.

Karatas M, Chaikuad A, Berger B, Kubbutat MHG, Totzke F, Knapp S, Kunick C. Karatas M, et al. Among authors: kubbutat mhg. Molecules. 2021 Mar 14;26(6):1611. doi: 10.3390/molecules26061611. Molecules. 2021. PMID: 33799460 Free PMC article.

2

Apoptosis and its relevance in cancer therapy.

Ehlert JE, Kubbutat MH. Ehlert JE, et al. Among authors: kubbutat mh. Onkologie. 2001 Oct;24(5):433-40. doi: 10.1159/000055123. Onkologie. 2001. PMID: 11694769 Review.

3

Hydrophobic Derivatives of Glycopeptide Antibiotics as Inhibitors of Protein Kinases.

Cozza G, Fortuna M, Meggio F, Sarno S, Kubbutat MHG, Totzke F, Schaechtele C, Pinna LA, Olsufyeva EN, Preobrazhenskaya MN. Cozza G, et al. Among authors: kubbutat mhg. Biochemistry (Mosc). 2018 Oct;83(10):1222-1230. doi: 10.1134/S0006297918100073. Biochemistry (Mosc). 2018. PMID: 30472959 Free PMC article.

4

Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors.

Schlütke L, Immer M, Preu L, Totzke F, Schächtele C, Kubbutat MHG, Kunick C. Schlütke L, et al. Among authors: kubbutat mhg. Eur J Pharm Biopharm. 2018 May;126:89-94. doi: 10.1016/j.ejpb.2017.03.011. Epub 2017 Mar 15. Eur J Pharm Biopharm. 2018. PMID: 28315448

5

New HPV E6 binding proteins: dangerous liaisons?

Kubbutat MH, Vousden KH. Kubbutat MH, et al. Trends Microbiol. 1998 May;6(5):173-5. doi: 10.1016/s0966-842x(98)01267-0. Trends Microbiol. 1998. PMID: 9614337 Review. No abstract available.

6

Dual IGF-1R/SRC inhibitors based on a N'-aroyl-2-(1H-indol-3-yl)-2-oxoacetohydrazide structure.

Schmidt S, Preu L, Lemcke T, Totzke F, Schächtele C, Kubbutat MH, Kunick C. Schmidt S, et al. Among authors: kubbutat mh. Eur J Med Chem. 2011 Jul;46(7):2759-69. doi: 10.1016/j.ejmech.2011.03.065. Epub 2011 Apr 6. Eur J Med Chem. 2011. PMID: 21524503

7

Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors.

Barbosa ML, Lima LM, Tesch R, Sant'Anna CM, Totzke F, Kubbutat MH, Schächtele C, Laufer SA, Barreiro EJ. Barbosa ML, et al. Among authors: kubbutat mh. Eur J Med Chem. 2014 Jan;71:1-14. doi: 10.1016/j.ejmech.2013.10.058. Epub 2013 Oct 31. Eur J Med Chem. 2014. PMID: 24269511

8

Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model.

Civit L, Theodorou I, Frey F, Weber H, Lingnau A, Gröber C, Blank M, Dambrune C, Stunden J, Beyer M, Schultze J, Latz E, Ducongé F, Kubbutat MHG, Mayer G. Civit L, et al. Among authors: kubbutat mhg. Sci Rep. 2019 Mar 21;9(1):4976. doi: 10.1038/s41598-019-41460-2. Sci Rep. 2019. PMID: 30899039 Free PMC article.

9

Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization.

Tasler S, Müller O, Wieber T, Herz T, Pegoraro S, Saeb W, Lang M, Krauss R, Totzke F, Zirrgiebel U, Ehlert JE, Kubbutat MH, Schächtele C. Tasler S, et al. Among authors: kubbutat mh. Bioorg Med Chem. 2009 Sep 15;17(18):6728-37. doi: 10.1016/j.bmc.2009.07.047. Epub 2009 Jul 25. Bioorg Med Chem. 2009. PMID: 19692247

10

Keeping an old friend under control: regulation of p53 stability.

Kubbutat MH, Vousden KH. Kubbutat MH, et al. Mol Med Today. 1998 Jun;4(6):250-6. doi: 10.1016/s1357-4310(98)01260-x. Mol Med Today. 1998. PMID: 9679243 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results